FDA approves Radicava, ALS Association applauds speedy process

The ALS Association, the only national nonprofit fighting amyotrophic lateral sclerosis (ALS) on every front, applauded the Food and Drug Administration's (FDA) announcement Friday that it has approved Radicava (edaravone), the first new treatment approved specifically for ALS in 22 years. The FDA approved Radicava less than a year after Mitsubishi Tanabe Pharma Corporation submitted ["]

The post FDA approves Radicava, ALS Association applauds speedy process appeared first on Outbreak News Today.